These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Human trials of AIDS vaccines: novel means of passive and active immunotherapy. Dalgleish AG AIDS; 1988; 2 Suppl 1():S129-31. PubMed ID: 3147663 [No Abstract] [Full Text] [Related]
4. Antigenic structures recognized by T cells: towards the rational design of an AIDS vaccine. Cease KB; Berzofsky JA AIDS; 1988; 2 Suppl 1():S95-101. PubMed ID: 3147685 [No Abstract] [Full Text] [Related]
5. Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts. Goudsmit J AIDS; 1988; 2 Suppl 1():S41-5. PubMed ID: 2465771 [No Abstract] [Full Text] [Related]
6. Part of AIDS virus is patented. Sun M Science; 1988 Feb; 239(4843):970. PubMed ID: 2830668 [No Abstract] [Full Text] [Related]
7. Patterns of antigenaemia and antibody response in patients infected with human immunodeficiency virus (HIV) according to clinical state. Re MC; Furlini G; La Placa M J Clin Pathol; 1989 Mar; 42(3):282-3. PubMed ID: 2703545 [TBL] [Abstract][Full Text] [Related]
8. Harming and protecting responses to HIV. Lanzavecchia A Res Immunol; 1989 Jan; 140(1):99-103; discussion 123-4. PubMed ID: 2567046 [No Abstract] [Full Text] [Related]
9. AIDS vaccines inch closer to useful existence. Goldsmith MF JAMA; 1991 Mar; 265(11):1356-7. PubMed ID: 1999873 [No Abstract] [Full Text] [Related]
10. Synergism between HIV gp120 and gp120-specific antibody in blocking human T cell activation. Mittler RS; Hoffmann MK Science; 1989 Sep; 245(4924):1380-2. PubMed ID: 2571187 [TBL] [Abstract][Full Text] [Related]
11. HIV-gag-specific cytotoxic T lymphocytes. Nixon DF; McMichael AJ Res Immunol; 1989 Jan; 140(1):107-10; discussion 121. PubMed ID: 2657907 [No Abstract] [Full Text] [Related]
12. Use of vaccinia virus vectors for development of AIDS vaccines. Moss B AIDS; 1988; 2 Suppl 1():S103-5. PubMed ID: 3147660 [No Abstract] [Full Text] [Related]
14. The CD4 antigen: physiological ligand and HIV receptor. Sattentau QJ; Weiss RA Cell; 1988 Mar; 52(5):631-3. PubMed ID: 2830988 [No Abstract] [Full Text] [Related]
15. Monitoring human immunodeficiency virus type 1-infected patients by ratio of antibodies to gp41 and p24. Schmidt G; Amiraian K; Frey H; Wethers J; Stevens RW; Berns DS J Clin Microbiol; 1989 May; 27(5):843-8. PubMed ID: 2501350 [TBL] [Abstract][Full Text] [Related]
16. [Detection of antibodies to the surface (anti-p-41) and nuclear protein (anti-p-24) of the human immunologic deficiency virus (HIV)]. Hess G; Kroegel C; Ramadori G; Rieder H; Meyer zum Büschenfelde KH Med Klin (Munich); 1987 Oct; 82(21):723-5, 761. PubMed ID: 3500393 [No Abstract] [Full Text] [Related]
17. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Lasky LA; Groopman JE; Fennie CW; Benz PM; Capon DJ; Dowbenko DJ; Nakamura GR; Nunes WM; Renz ME; Berman PW Science; 1986 Jul; 233(4760):209-12. PubMed ID: 3014647 [TBL] [Abstract][Full Text] [Related]
18. The prospects for AIDS vaccines. Koff WC Hosp Pract (Off Ed); 1991 Apr; 26(4):99-106. PubMed ID: 2010483 [TBL] [Abstract][Full Text] [Related]
19. Second AIDS trial. Ezzell C Nature; 1988 Jan; 331(6154):290. PubMed ID: 2829025 [No Abstract] [Full Text] [Related]
20. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Berzofsky JA; Bensussan A; Cease KB; Bourge JF; Cheynier R; Lurhuma Z; Salaün JJ; Gallo RC; Shearer GM; Zagury D Nature; 1988 Aug; 334(6184):706-8. PubMed ID: 2457809 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]